GlassScriptPhysician profile
Arslan Naeem
NPI 1962856773
$3,045.53
in general payments reported to CMS, 2019-2025
24 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2021: $201 · 2022: $401 · 2023: $848 · 2024: $1,237 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831 · Education: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.51 |
| Education | $482.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $766.84 | 2021-2024 | Diamondback Coronary, Supera, Perclose Prostyle |
| Abiomed | $387.58 | 2021-2025 | Impella |
| Chiesi USA, INC. | $185.36 | 2022-2023 | Kengreal |
| Shockwave Medical, INC | $169.99 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Asahi Intecc USA, INC. | $142.17 | 2024 | Peripheral Vascular |
| Astrazeneca Pharmaceuticals LP | $141.55 | 2024 | Lokelma, Farxiga |
| Medtronic, INC. | $134.97 | 2023-2025 | Symplicity G3, Onyx Frontier, Flexcath Advance |
| Novartis Pharmaceuticals Corporation | $133.69 | 2023-2024 | |
| Inari Medical, INC. | $114.48 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $101.09 | 2024-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $90.41 | 2024 | |
| Pfizer INC. | $87.06 | 2024 | |
| Medtronic Vascular, INC. | $71.94 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.74 | 2022-2025 | Lifevest |
| Teleflex LLC | $66.98 | 2024 | Turnpike |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.66 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $60.47 | 2023-2024 | Xarelto |
| Boston Scientific Corporation | $58.44 | 2019 | |
| Merck Sharp & Dohme LLC | $48.37 | 2024 | Verquvo |
| Penumbra, INC. | $48.00 | 2023 | Indigo System |
| Novo Nordisk INC | $38.74 | 2025 | Rybelsus, Ozempic |
| Terumo Medical Corporation | $24.46 | 2023 | Azur Cx Detachable |
| Lantheus Medical Imaging, INC. | $20.56 | 2022 | |
| Janssen Biotech, INC. | $19.98 | 2024 | Tecvayli, Talvey |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arslan Naeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.